AR055070A1 - Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso - Google Patents
Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su usoInfo
- Publication number
- AR055070A1 AR055070A1 ARP060102820A ARP060102820A AR055070A1 AR 055070 A1 AR055070 A1 AR 055070A1 AR P060102820 A ARP060102820 A AR P060102820A AR P060102820 A ARP060102820 A AR P060102820A AR 055070 A1 AR055070 A1 AR 055070A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- pharmaceutical composition
- preparation
- same
- active agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002459 sustained effect Effects 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 3
- 239000003443 antiviral agent Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 238000013268 sustained release Methods 0.000 abstract 2
- 239000012730 sustained-release form Substances 0.000 abstract 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 abstract 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 abstract 1
- 229960001058 bupropion Drugs 0.000 abstract 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 abstract 1
- 229960000830 captopril Drugs 0.000 abstract 1
- 229960001380 cimetidine Drugs 0.000 abstract 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 abstract 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 abstract 1
- 229960003592 fexofenadine Drugs 0.000 abstract 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 abstract 1
- 229960004002 levetiracetam Drugs 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 abstract 1
- 229960000620 ranitidine Drugs 0.000 abstract 1
- 229960004380 tramadol Drugs 0.000 abstract 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composicion farmacéutica de liberacion sostenida que comprende por lo menos un agente activo o sus formas tautoméricas, análogos, isomeros, polimorfos, solvatos o sales de los mismos; preferiblemente se provee un agente activo antiviral. También se provee un proceso de preparacion de tal composicion y método para su utilizacion. Las composiciones de liberacion sostenida de la presente pueden suministrar el agente activo de manera deseada durante un período prolongado. Uso. Reivindicacion 2: Una composicion tal como se reivindica en (1), caracterizada porque el agente activo se selecciona de un grupo que comprende un agente antiviral, cimetidina, ranitidina, captopril, metformina, bupropion, fexofenadina, oxcarbacepina, levetiracetam, tramadol o sus formas tautoméricas, análogos, isomeros, polimorfos, solvatos, derivados o sales de los mismos utilizados solos o en combinacion.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1680DE2005 | 2005-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055070A1 true AR055070A1 (es) | 2007-08-01 |
Family
ID=37027780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102820A AR055070A1 (es) | 2005-06-29 | 2006-06-29 | Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20090099154A1 (es) |
| EP (1) | EP1912628A2 (es) |
| JP (1) | JP2009500318A (es) |
| CN (1) | CN101212957A (es) |
| AR (1) | AR055070A1 (es) |
| AU (1) | AU2006263338A1 (es) |
| BR (1) | BRPI0613070A2 (es) |
| CA (1) | CA2613407A1 (es) |
| CR (1) | CR9705A (es) |
| EA (1) | EA200800162A1 (es) |
| MX (1) | MX2008000084A (es) |
| NO (1) | NO20080399L (es) |
| RS (1) | RS20070512A (es) |
| TN (1) | TNSN07490A1 (es) |
| WO (1) | WO2007000779A2 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2428205T3 (da) | 2006-03-16 | 2012-10-22 | Tris Pharma Inc | Modificerede formuleringer indeholdende lægemiddel-ionbytterharpikskomplekser |
| MX2008015571A (es) * | 2006-06-08 | 2009-04-24 | Univ Yale | Metodo de destilado de columna de etapa multiple (mscd) para recuperacion de una sustancia disuelta osmotica. |
| EP2101743B1 (en) * | 2006-12-15 | 2010-06-23 | Campina Nederland Holding B.V. | Extended release excipient and its use |
| EP1935411A1 (en) | 2006-12-15 | 2008-06-25 | Campina Nederland Holding B.V. | Slow release excipient and its use |
| MX2009007913A (es) * | 2007-01-25 | 2009-07-31 | Panacea Biotec Ltd | Composicion farmaceutica de liberacion modificada y un procedimiento para elaborarla. |
| HUE028598T2 (en) | 2007-06-08 | 2016-12-28 | Boehringer Ingelheim Int | Extended release nevirapine preparation |
| MY147827A (en) * | 2007-10-19 | 2013-01-31 | Otsuka Pharma Co Ltd | Pharmaceutical solid preparation |
| WO2010026467A2 (en) * | 2008-09-04 | 2010-03-11 | Torrent Pharmaceuticals Ltd. | Controlled release dosage form of high solubility active ingredient |
| RU2607595C2 (ru) * | 2010-02-03 | 2017-01-10 | Фарма Ту Б Лтд. | Составы разагилина с пролонгированным высвобождением и их применение |
| WO2011117875A1 (en) * | 2010-03-26 | 2011-09-29 | Hetero Research Foundation | Salts of fluvastatin and process for the preparation of substantially amorphous fluvastatin sodium |
| KR20120055313A (ko) * | 2010-11-23 | 2012-05-31 | 주식회사 바이오파마티스 | 레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법 |
| CN102058553B (zh) * | 2010-12-28 | 2012-10-10 | 哈药集团三精制药股份有限公司 | 阿昔洛韦缓释片及其制备方法 |
| CA2847614C (en) | 2011-09-30 | 2018-10-23 | Mochida Pharmaceutical Co., Ltd. | Easily dosable solid preparation |
| FR2983409B1 (fr) | 2011-12-06 | 2013-12-27 | Ethypharm Sa | Comprime susceptible de lutter contre le detournement par voie injectable |
| JP2013119540A (ja) * | 2011-12-08 | 2013-06-17 | Nipro Corp | 固形医薬組成物およびその製造法 |
| AU2013235345B2 (en) | 2012-03-21 | 2016-03-24 | Galleon Labs Llc | Topically administered strontium-containing complexes for treating pain, pruritis and inflammation |
| WO2014181390A1 (ja) * | 2013-05-08 | 2014-11-13 | 全星薬品工業株式会社 | 機能性高分子皮膜で被覆された高含量薬物粒子およびそれを含む錠剤ならびにそれらの製造方法 |
| US20160193182A1 (en) * | 2013-08-14 | 2016-07-07 | Evonik Roehm Gmbh | Coating composition |
| US20160250253A1 (en) * | 2013-09-24 | 2016-09-01 | Cosmederm Bioscience, Inc. | Strontium-containing complexes for treating gastroesophageal reflux and barrett's esophagus |
| CN103705933A (zh) * | 2013-12-18 | 2014-04-09 | 北京科源创欣科技有限公司 | 奥卡西平药物组合物及制备方法 |
| JP6532765B2 (ja) * | 2014-06-06 | 2019-06-19 | 株式会社ファンケル | 即効性成分と持続性成分を含む錠剤 |
| US10111838B2 (en) * | 2014-11-26 | 2018-10-30 | Evonik Roehm Gmbh | Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol |
| CN104666267B (zh) * | 2015-03-27 | 2017-08-08 | 康普药业股份有限公司 | 一种阿昔洛韦药物组合物 |
| US11235002B2 (en) | 2015-08-21 | 2022-02-01 | Galleon Labs Llc | Strontium based compositions and formulations for pain, pruritus, and inflammation |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| JP6326114B2 (ja) * | 2016-11-01 | 2018-05-16 | エルメッド エーザイ株式会社 | レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤 |
| KR102329377B1 (ko) * | 2017-02-03 | 2021-11-19 | 가부시키가이샤 도요 신야쿠 | 고형 제제 |
| CN106943356B (zh) * | 2017-05-10 | 2019-11-08 | 武汉人福药业有限责任公司 | 一种泛昔洛韦缓释颗粒剂及其制备方法 |
| JP6958856B2 (ja) * | 2017-08-09 | 2021-11-02 | 日本臓器製薬株式会社 | 錠剤 |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| CN109466152B (zh) * | 2018-09-04 | 2021-01-26 | 浙江罗奇泰克科技股份有限公司 | 一种高导热铁基板的制作方法 |
| EP4271380A4 (en) * | 2020-12-29 | 2025-01-22 | Abbvie Inc. | UPADACITINIB EXTENDED RELEASE FORMULATIONS |
| WO2024176162A1 (en) * | 2023-02-22 | 2024-08-29 | Sun Pharmaceutical Industries Limited | Stable pharmaceutical composition of histamine h2‐receptor antagonist |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE77165B1 (en) * | 1991-01-30 | 1997-12-03 | Wellcome Found | Water-dispersible tablet containing acyclovir |
| US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5695781A (en) * | 1995-03-01 | 1997-12-09 | Hallmark Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers |
| US20030134864A1 (en) * | 1996-02-07 | 2003-07-17 | Smithkline Beecham P.L.C. | Activity of penciclovir against epstein-barr virus |
| IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| MXPA01002634A (es) * | 1998-09-14 | 2002-06-04 | Ranbaxy Lab Ltd | Sistema de entrega que controla a una droga oralmente administrada proporcionando control en tiempo y espacial. |
| WO2002102415A1 (en) * | 2001-06-18 | 2002-12-27 | Blue Cross Laboratories Limited | Gastric floating system |
| AU2003255871A1 (en) * | 2002-08-14 | 2004-03-03 | Ranbaxy Laboratories Limited | Extended release matrix tablets |
| US20050112198A1 (en) * | 2003-10-27 | 2005-05-26 | Challapalli Prasad V. | Bupropion formulation for sustained delivery |
-
2006
- 2006-06-29 RS RSP-2007/0512A patent/RS20070512A/sr unknown
- 2006-06-29 EA EA200800162A patent/EA200800162A1/ru unknown
- 2006-06-29 AR ARP060102820A patent/AR055070A1/es not_active Application Discontinuation
- 2006-06-29 US US11/922,960 patent/US20090099154A1/en not_active Abandoned
- 2006-06-29 AU AU2006263338A patent/AU2006263338A1/en not_active Abandoned
- 2006-06-29 BR BRPI0613070-4A patent/BRPI0613070A2/pt not_active IP Right Cessation
- 2006-06-29 WO PCT/IN2006/000225 patent/WO2007000779A2/en not_active Ceased
- 2006-06-29 CN CNA2006800239073A patent/CN101212957A/zh active Pending
- 2006-06-29 EP EP06766278A patent/EP1912628A2/en not_active Withdrawn
- 2006-06-29 MX MX2008000084A patent/MX2008000084A/es unknown
- 2006-06-29 JP JP2008519142A patent/JP2009500318A/ja not_active Withdrawn
- 2006-06-29 CA CA002613407A patent/CA2613407A1/en not_active Abandoned
-
2007
- 2007-12-28 TN TNP2007000490A patent/TNSN07490A1/en unknown
-
2008
- 2008-01-21 NO NO20080399A patent/NO20080399L/no not_active Application Discontinuation
- 2008-01-29 CR CR9705A patent/CR9705A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007000779A2 (en) | 2007-01-04 |
| MX2008000084A (es) | 2008-03-18 |
| CN101212957A (zh) | 2008-07-02 |
| CR9705A (es) | 2008-10-30 |
| US20090099154A1 (en) | 2009-04-16 |
| BRPI0613070A2 (pt) | 2010-12-21 |
| JP2009500318A (ja) | 2009-01-08 |
| AU2006263338A1 (en) | 2007-01-04 |
| EA200800162A1 (ru) | 2008-06-30 |
| NO20080399L (no) | 2008-03-31 |
| CA2613407A1 (en) | 2007-01-04 |
| EP1912628A2 (en) | 2008-04-23 |
| RS20070512A (sr) | 2009-01-22 |
| TNSN07490A1 (en) | 2009-03-17 |
| AU2006263338A2 (en) | 2008-06-05 |
| WO2007000779A3 (en) | 2007-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR055070A1 (es) | Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso | |
| UY27516A1 (es) | Bencimidazoles | |
| CR7069A (es) | Derivados de pirazol para el tratamiento de vih | |
| AR055076A1 (es) | Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica. | |
| GT200100132A (es) | Derivados de pirazol | |
| UY28510A1 (es) | Compuestos quimicos | |
| UY28671A1 (es) | Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2 | |
| ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
| CL2009001059A1 (es) | Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras. | |
| PA8518801A1 (es) | Derivados de 2-aminocarbonil-9h-purina | |
| CL2011001658A1 (es) | Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor. | |
| PA8577101A1 (es) | Nuevos derivados de glicosido de tiofeno, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
| UY28800A1 (es) | 5,6-dialquil-7-amino-triazolopirimidinas, procedimientos para su preparación y el uso de las mismas para combatir hongos nocivos | |
| CR9954A (es) | Derivados de pirazina | |
| UY28026A1 (es) | 4-piperazinilbencenosulfonilindoles y usos de los mismos. | |
| CR8278A (es) | Combinaciones sinergicas de productos activos, fungicidas | |
| ECSP088329A (es) | Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8 | |
| GT200900001A (es) | Composicion farmaceutica que contiene un acido tetra hidrofolico | |
| ECSP088296A (es) | Compuestos terapéuticos | |
| PA8582801A1 (es) | Nuevos derivados espirotricíclicos y su uso como inhibidores de la fosfodiesterasa | |
| CU23779B7 (es) | Compuestos de pirazolina y su uso y composiciones farmacéuticas | |
| PA8568101A1 (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso | |
| ECSP044999A (es) | Agentes antidiabeticos | |
| GT200500309A (es) | Derivados de sulfonilbencilimidazol | |
| AR044200A1 (es) | Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |